Increased risk for lethal forms of liver disease among HBsAg-positive blood donors in the United States.
We have used a death-record search to define the frequency of lethal outcomes of hepatitis B virus infection among a population of more than 15,000 overtly healthy blood donors found positive in routine HBsAg testing. We have compared the study population with a control group of some 18,000 donors selected on the basis of a negative test result. The index and control groups were observed for periods reflecting a total of 55 and 59 thousand person-years, respectively. Twenty percent of the 134 deaths identified among HBsAg positive donors were in some way liver related, including seven deaths due to hepatitis, seven to cirrhosis and six to hepatoma. In contrast, only one of the 95 deaths in the control population was liver related, and was due to fatty degeneration of the liver. The majority (four) of the hepatoma deaths occurred among blacks, three of whom were less than 35 at the time of death. In contrast, deaths from cirrhosis were all among whites. We conclude that there is significant mortality associated with the HBsAg positive state, even though the affected individuals may be asymptomatic and well enough to give blood at some stage. We estimate the standardised mortality ratio for hepatoma among HBsAg-positive persons in the United States is at least 27, confirming the association observed in other populations. The risk for hepatoma among young, HBsAg positive black males appears to approach that reported for HBsAg positive males in Taiwan. Data on the feasibility of AFP testing for early detection of hepatoma are included and discussed.
D001782:Blood Donors; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000401:mortality*; D002353:Carrier State; D002423:Cause of Death; D005260:Female; D006509:Hepatitis B / Q000150:complications / Q000401:mortality*; D006514:Hepatitis B Surface Antigens; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications / Q000401:mortality*; D008113:Liver Neoplasms / Q000150:complications / Q000401:mortality*; D008297:Male; D012307:Risk Factors; D012984:Software; D014481:United States; D000509:alpha-Fetoproteins / Q000032:analysis
D006514:Hepatitis B Surface Antigens; D000509:alpha-Fetoproteins